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Piwi proteins and their interaction with piRNAs have rapidly emerged as important contributors to gene regulation, indicating their
crucial function in germline and stem cell development. However, data on the Hiwi 1 (Hiwi) gene, one of the four human Piwi
homologues, are still scarce. Therefore, we investigated the Hiwi mRNA expression in microdissected PDAC tissues from patients
with ductal adenocarcinoma of the pancreas (PDAC) by quantitative real-time PCR and the protein expression by
immunohistochemistry. Elevated levels of Hiwi mRNA transcripts were measured in 40 out of 56 tissues and a positive
immunostaining of Hiwi was detected in tumours of 21 out of 78 patients. There was no general impact of elevated Hiwi mRNA
transcript levels or protein expression on survival, as tested by multivariate Cox regression and Kaplan–Meier analysis. However, men
showed a significantly increased risk for tumour-related death in case of down- or upregulated expression of Hiwi mRNA (relative
risk (RR)¼2.78; P¼0.034). In summary, we report the first analysis of Hiwi expression in PDAC and its impact on prognosis.
We suggest that alterations in mRNA expression of Hiwi can increase the risk of tumour-related death in male PDAC patients.
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Current stem cell genetic research provides only scarce data on
Hiwi 1 (Hiwi) – one of four human homologues of the Piwi gene
family – despite growing focus of studies on the latter and its
interacting RNAs (piRNAs), for which a key function in
transcriptional gene silencing and germline/stem cell development
in flies and mammals has been demonstrated (Aravin et al, 2007;
Seto et al, 2007; Farazi et al, 2008). Data on Piwi proteins, a
subfamily of Argonaute proteins, highlight their impressive
biological capacities, such as biogenesis/regulation of small RNAs,
control of protein synthesis and mRNA stability, showing
conserved functions in maintenance and self-renewal of stem cells
(Seto et al, 2007; Hutvagner et al, 2008).
It has been suggested that deregulation of stem cell self-
renewal may cause the development of malignancies because
normal stem cells share several similarities with so-called
tumour stem cells, for example, the ability to self-renew and
a relative resistance to drugs (Soltysova et al, 2005; Chen et al,
2007; Taubert et al, 2007a). Besides being expressed abundantly
in germline cells of human testes, Hiwi’s enhanced expression
was detected in testicular seminomas, which originate from
embryonic germ cells with retention of a germ cell phenotype
(Qiao et al, 2002). This has given rise to the assumption that
Hiwi overexpression may be involved in the development of
germ cell malignancy, prompting further investigation on other
human malignancies. Consequently, it has been shown that
expression of the Hiwi gene in human gastric cancer was
associated with the proliferation of cancer cells (Liu et al, 2006).
Moreover, in patients with soft-tissue sarcoma, elevated Hiwi
mRNA transcript levels were associated with a significantly
increased risk of tumour-related death (Taubert et al, 2007a,b).
However, Hiwi was not detectable in leukaemia cell lines (Sharma
et al, 2001).
Ductal adenocarcinoma of the pancreas (PDAC), a dismal
disease with a late clinical presentation and a very poor overall
prognosis (Yeo et al, 2002), seems to be an interesting subject to
investigate with regards to the involvement of stem cell-associated
genes and Hiwi in particular. The main features of PDAC–
aggressive biological phenotype, early local invasion with high
metastatic potential and a high resistance to radiation and
chemotherapy (Yeo et al, 2002)–suggest the involvement of cells
with stem cell characteristics in PDAC. Analysis of the stem cell-
associated gene Hiwi in this malignancy might provide important
clues to the understanding of this disease.
Besides the above listed tumour entities, no studies on
other malignancies, particularly on PDAC, on the involvement
of Hiwi expression in tumour development have been reported,
and the impact of Hiwi expression on patients’ prognosis has
only been studied in soft-tissue sarcomas yet (Taubert et al,
2007a,b). Therefore, the aim of our study was to investigate the
expression profile of Hiwi and its impact on prognosis in PDAC
patients.
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Patients
We analysed a cohort of patients who underwent primary surgery
for PDAC in the years 2001–2005 in our clinic (Department of
Surgery 1, University of Ulm, Germany). Paraffin-embedded tissue
of 78 patients (31 females and 47 males, age range 34–80 years;
mean age 61.1 years) was obtained. Furthermore, fresh-frozen
tissue of 56 patients (22 females and 34 males, age range 34–80
years; mean age 61.7 years) was conserved. All patients from whom
fresh-frozen tissue suitable for microdissection (sufficient amount
of neoplastic cells per sample (total of 44000 cells per patient) and
intact RNA (as tested with Agilent Bioanalyzer, see below) was
obtained were included in the study. The mean observation time
was 15.99 (range 1–61) months and the median survival rate was
15.26 (range 1–52) months. Four patients died from non-tumour-
related causes. None of the patients has received neoadjuvant
chemo- or radiotherapeutic treatment. All patients included in the
study gave written informed consent. The approval of the local
ethics committee was obtained.
Microdissection and QRT–PCR analysis
Fresh-frozen tissue samples from 56 PDAC patients were micro-
dissected to exclude stromal tissue and highly enrich neoplastic
cells (Burgemeister et al, 2003). Surgical pancreatic resection
specimens were immediately placed on ice and subsequently snap-
frozen, then stored at  801C. The integrity of the isolated RNA
(using Innuprep RNA mini kit, AJ Innuscreen GmbH, Berlin,
Germany) was confirmed with the Agilent 2100 Bioanalyzer
(Agilent Technologies, Santa Clara, CA, USA). The cryostat tissues
were cut into 8–10-mm sections. Microdissection of selected
areas (containing approximately 50–300 neoplastic ductal epithe-
lial cells per dissected area, 44000 cells per patient per tissue) was
carried out by Laser microdissection and pressure catapulting
technique (PALM Microlaser Technologies, Bernried, Germany) on
cresyl violet-stained sections (Supplementary Figures). Subse-
quently, we performed quantitative real-time PCR analysis for the
expression of Hiwi mRNA. The mRNA expression of Hiwi was
quantified by a commercially available TaqMan gene expression
assay (Assay-ID: Hs01041737_ml; Applied Biosystems, Foster City,
CA, USA) and standardised to the transcript level of hypoxanthin-
phospho-ribosyl-transferase (HPRT), using TaqMan gene expres-
sion assay (Assay-ID: Hs99999909_ml; Applied Biosystems).
Immunohistochemistry
Analysis of 78 PDAC tissue specimens by immunohistochemistry
(IHC) was performed. All specimens were fixed in buffered
formalin and embedded in paraffin. Sections of 4-mm thickness
were deparaffinised in xylene and rehydrated. After microwave-
heating of the sections in citrate buffer at 450W for 2min and
subsequently at 80W for 20min, slides were cooled to room
temperature, then treated with peroxidase-blocking reagent
(DakoCytomation, Dako, Hamburg, Germany) and serum-block-
ing reagent (VECTASTAIN Elite ABC Kit; Vector Lab., Burlingame,
CA, USA). Sections were incubated overnight at 41C with an 1:250
diluted goat anti-human polyclonal Hiwi antibody (HIWI N-17:sc-
22685; Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA). The
slides were further treated with the VECTASTAIN Elite ABC Kit,
according to the manufacturer’s instructions using a secondary
biotinylated Anti-goat-IgG antibody. Diaminobenzidine was used
as chromogen and the sections were counterstained with Mayer
haematoxylin. All washing steps were performed in Tris-buffer.
Immunohistochemical evaluation was carried out by at least two
independent investigators. At least 500 neoplastic ductal cells were
counted/examined per tissue section. Positive staining required a
minimum of 10% of neoplastic cells exhibiting a distinct staining.
Three patterns of staining intensity were defined: strong, inter-
mediate and weak staining. Testicular seminomas served as
positive control.
Statistical analysis
Kaplan–Meier and multivariate survival analysis according to the
Cox’s proportional hazards regression model (adjusted for tumour
staging, type of tumour resection, patients’ age and gender) was
performed for evaluation of Hiwi mRNA expression and IHC
results. First, two categories of Hiwi levels were set up for analysis
of mRNA transcript levels: (1) ‘No expression’ (o0.001 attogram
(ag) Hiwi mRNA per (femtogram) fg HPRT mRNA); (2) ‘Elevated
expression’ (X0.001ag Hiwi mRNA per fg HPRT mRNA). Second,
analyses using the mean and median values as cutoff levels were
performed. Accordingly, threshold levels were set at 1.12 and
0.62ag Hiwi mRNA per fg HPRT mRNA, respectively. A third
analysis applied the quartile of Hiwi mRNA expression and
resulted in four groups, that is, two groups with low expression
(o0.061ag Hiwi mRNA per fg HPRT mRNA; n¼27), a group with
intermediate expression (intermediate expression X0.061–
o0.568ag Hiwi mRNA per fg HPRT mRNA; n¼15) and a group
with high expression (X0.568ag Hiwi mRNA per fg HPRT mRNA;
n¼14). In this analysis, we combined groups with the low and
high expression profile and compared their joint expression with
the intermediate expression group. The SPSS 15.0 software was
used for statistical analysis. Values of Po0.05 were considered
significant.
RESULTS
Pattern of Hiwi expression
Elevated transcript levels of Hiwi mRNA were measured in 40 out
of 56 PDAC tissues (71.4%), whereas the remaining patients
showed no detectable transcripts. The mean expression level of
Hiwi transcripts was 1.12 (range: 0.00–28.24; median: 0.62) ag
Hiwi mRNA per fg HPRT mRNA. Patients whose tumours showed
an expression below or above the mean or median, revealed
an equal distribution between tumour stages, resection types
(R-status), age and gender (Table 1).
In IHC, positive immunostaining with the anti-HIWI N-17
antibody was detected in 21 out of 78 samples (26.9%), whereas the
remaining 57 tumours showed no positive staining in more than
10% of the cells (Table 2). Of the 21 positively stained tumours, 11
(14.1%) showed a simultaneous immunostaining in the nucleus
and cytoplasm of the neoplastic ductal cells and 10 (12.8%)
demonstrated a sole cytoplasmatic staining pattern (Figure 1).
A total of 17 tumours showed a strong and 4 a moderate staining
intensity, whereas a weak staining was not observed among the
tumour samples. Patients with a Hiwi expression on protein level
showed an equal distribution between the tumour stages, resection
types, age and gender.
Clinical outcome and Hiwi expression
In Kaplan–Meier and multivariate Cox’s regression hazard
analysis (adjusted to tumour resection type and tumour stage)
no impact of Hiwi mRNA expression on survival was determined
in a comparison of groups of patients whose tumours expressed
Hiwi either below or above the median/mean level of expression.
Furthermore, separation of patients in two groups with tumours
expressing undetectable levels (o0.001ag Hiwi mRNA per fg
HPRT mRNA) or detectable levels of Hiwi transcripts (X0.001ag
Hiwi mRNA per fg HPRT mRNA) did not show an impact of Hiwi
expression on survival (RR¼1.401; P¼0.328). These findings
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patients with soft-tissue sarcoma, we identified three groups of
patients, where patients with an elevated or a reduced Hiwi
expression in their tumours showed a poor prognosis compared
to patients with an intermediate expression level (Taubert et al,
2007a). Therefore, we separated patients into a group where
tumours carried a high or a low expression of Hiwi transcripts
and a group with intermediate Hiwi expression. We performed
this separately for female and for male patients. In a multivariate
Cox’s regression analysis in male patients, we detected a 2.78-fold
increased risk of tumour-related death for patients (P¼0.034)
whose tumours showed an elevated or a decreased expression
of Hiwi compared to patients with an intermediate expression
of Hiwi (Figure 2). Interestingly, for female patients no different
impact on prognosis could be found comparing both patient
groups.
Table 1 Hiwi mRNA: clinical and histopathological data of ductal adenocarcinoma of the pancreas patients
Stage
Patient no. Age at surgery Sex Survival (months) T N M R-status Grading Hiwi mRNA (in ag/fg HPRT)
1 59 M 13 3 1 0 0 2 28.241
2 53 F 16 3 1 0 0 2 0.038
3 60 F 21 3 0 0 0 2 1.366
4 64 M Alive
a 3 0 0 1 3 0.139
5 40 F 19 3 1 0 0 3 0.010
6 59 M 24 3 1 0 0 3 0.979
7 47 F 20 3 1 0 0 2 0.072
8 46 F 15 3 1 0 0 2 1.825
9 71 M 5 3 0 0 1 3 0.576
10 66 F 4 4 1 0 2 1 0.000
11 70 M 15 3 1 0 1 3 7.689
12 67 M 6 3 1 0 0 2 0.000
13 74 M 3 4 1 1 2 1 0.523
14 75 F 49 3 1 0 0 2 1.139
15 49 M 22 3 1 0 0 1 1.112
16 70 M 4 3 1 0 0 3 2.526
17 68 M 11 3 0 0 0 3 0.000
18 72 F 33 3 1 0 1 2 0.935
19 73 F 1 3 1 0 0 1 0.000
20 58 M 43 3 2 0 0 2 0.077
21 74 M Alive
a 3 1 0 0 3 0.003
22 69 F 15 4 2 1 2 3 0.060
23 43 M 2 3 2 1 2 3 0.000
24 56 M 5 4 2 1 2 2 0.069
25 48 M 9 2 1 0 0 3 0.000
26 70 M 8 4 2 1 2 2 0.141
27 76 M 15 3 0 0 0 2 0.063
28 57 F 3 4 0 0 0 3 0.053
29 61 M 14 2 1 0 0 3 0.030
30 69 M 9 3 1 0 0 2 0.545
31 47 M 2 3 1 0 0 3 5.160
32 52 F 29 3 0 0 0 2 0.000
33 38 F 4 4 2 1 2 1 0.112
34 65 M 16 3 0 0 0 3 0.074
35 75 M 13 3 0 0 0 2 0.010
36 60 F 4 3 1 1 1 3 0.015
37 61 F 37 3 1 0 0 2 0.005
38 62 F 16 3 0 0 1 2 0.000
39 80 M 33 3 1 0 0 1 0.000
40 69 F 1 3 1 0 0 2 0.027
41 42 M 3 4 2 1 2 3 0.050
42 52 M Alive
a 3 1 0 0 3 0.000
43 52 M 13 3 1 0 0 3 0.000
44 71 F 23 3 0 0 0 2 2.374
45 64 F Alive
a 1 1 0 0 2 0.000
46 69 M Alive
a 3 1 0 0 1 0.109
47 68 F Alive
a 2 0 0 0 2 0.203
48 34 M 6 3 1 0 1 3 0.000
49 61 F 12 2 0 0 0 3 0.114
50 71 M 12 3 0 0 0 2 0.000
51 66 M 17 3 1 0 0 2 2.920
52 71 F 11 3 1 0 2 3 3.213
53 67 M 17 3 1 0 0 3 0.182
54 67 M 6 3 1 0 1 3 0.000
55 69 M 5 3 1 1 2 2 0.000
56 55 M 8 3 1 0 1 3 0.016
aAt follow-up.
Hiwi: expression and prognosis in PDAC
LF Grochola et al
1085
British Journal of Cancer (2008) 99(7), 1083–1088 & 2008 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sEvaluating the results obtained from immunohistochemistry,
no impact of Hiwi protein expression on tumour-related death
was found. No effect on patients’ prognosis was observed either
for isolated cytoplasmatic staining or simultaneous staining of
the nucleus and cytoplasm. There was no significant impact on
the patients’ gender and Hiwi protein expression on survival, as
evaluated by IHC.
DISCUSSION
Here, we report the first analysis of Hiwi mRNA and protein
expression in PDAC and its relation to prognosis. Consistent with
Table 2 Immunohistochemistry – summary of clinical and histopathological data
Total (n¼78)
HIWI staining
a Patients at follow-up
CP (n¼10) CP/nucleus (n¼11) No staining (n¼57) Alive
b (n¼10) Dead
c (n¼68)
Men/women 47/31 7/3 6/5 34/23 5/5 42/26
Tumour stage (%)
I 6 1 (16.7%) 2 (33.3%) 3 (50.0%) 2 (33.3%) 4 (66.6%)
II 12 1 (8.3%) 0 (0%) 11 (91.6%) 2 (16.7%) 10 (83.3%)
III 53 7 (13.2%) 7 (13.2%) 39 (73.6%) 6 (11.3%) 47 (88.7%)
IV 7 1 (14.3%) 2 (28.6%) 4 (57.1%) 0 (0%) 7 (100%)
Tumour resection (%)
Radical (R0) 60 7 (11.7%) 8 (13.3%) 45 (75.0%) 9 (15.0%) 51 (85.0%)
Not radical (R1) 11 1 (9.1%) 2 (18.2%) 8 (72.7%) 1 (9.1%) 10 (90.1%)
Not radical (R2) 7 2 (28.6%) 1 (14.3%) 4 (57.1%) 0 (0%) 7 (100%)
Tumour grading (%)
G1 7 1 (14.3%) 0 (0%) 6 (85.7%) 2 (28.6%) 5 (71.4%)
G2 30 5 (16.7%) 4 (13.3%) 21 (70%) 4 (13.3%) 26 (86.7%)
G3 41 4 (9.7%) 7 (17.1%) 30 (73,2%) 4 (9.7%) 37 (90.3%)
Patients at follow-up (%)
Alive
b 10 0 (0%) 2 (20.0%) 8 (80.0%) 10
Dead
c 68 10 (14.7%) 9 (13.2%) 49 (72.1%) 68
Data are the number of patients.
aStaining patterns: CP–isolated cytoplasmatic staining; CP/nucleus–simultaneous cytoplasmatic and nuclear staining.
bAfter an average
observation time of 15.99 (range 1–61) months.
cPatients died after an average of 15.26 (range 1–49) months, four patients died from non-tumour-related causes.
Figure 1 Immunohistochemical staining for Hiwi in ductal adenocarci-
noma of the pancreas. Cytoplasmatic expression in neoplastic ductal
carcinoma cells. (A:  100; B:  400).
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Figure 2 Multivariate Cox’s regression analysis: Hiwi mRNA expression
in two male patient groups (adjusted to tumour stage and type of
resection) in ductal adenocarcinoma of the pancreas: a group that includes
patients whose tumours showed low or high expression of Hiwi mRNA,
(n¼24) carries a 2.78-fold increased risk of tumour-related death
(P¼0.034) compared to patients whose tumours had an intermediate
Hiwi transcript level (n¼10).
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might not only be relevant in germ cell malignancies but also in
solid tumours of epithelial or mesenchymal origin (Qiao et al,
2002; Liu et al, 2006; Taubert et al, 2007a,b). Besides testicular
tumours, so far the expression of the human homologue of the
Piwi gene has only been investigated in leukaemia cell lines
(Sharma et al, 2001), gastric cancer (Liu et al, 2006) and soft-tissue
sarcomas (Taubert et al, 2007a,b), demonstrating elevated protein
and/or mRNA transcript levels in the two latter kinds of tumours.
Elevated and reduced Hiwi mRNA message were significantly
associated with a poor outcome in soft-tissue sarcoma patients,
outlining its possible key function in non-germ cell malignancies
(Taubert et al, 2007a,b). Accordingly, we observed a high
detection rate of Hiwi mRNA transcripts in our cohort, with
elevated mRNA levels detectable in 40 out of 56 patients.
Regarding survival analysis, no impact of Hiwi mRNA expres-
sion on tumour-related death was ascertained for all PDAC
patients. However, when only male patients were considered,
a 2.78-fold increased risk of tumour-related death was detected
for patients whose tumour showed an altered, that is, down- or
upregulated expression of Hiwi mRNA compared to those with an
intermediated Hiwi transcript level. The gender-dependent impact
of Hiwi mRNA expression on prognosis is not easy to explain.
Hiwi expression has been detected in normal human testes
and male germline malignancies, but was not detectable in ovaries
(Qiao et al, 2002). Moreover, mice bearing targeted mutations
in the murine-homologues Miwi (Deng and Lin, 2002), Mili
(Kuramochi-Miyagawa et al, 2004) and Miwi2 (Girard et al, 2006)
are male-sterile with distinct defects in spermatogenesis. However,
in lower eukaryotic organisms, such as Drosophila, mutations of
the Piwi gene caused failure in germline stem cells in both females
and males (Cox et al, 1998). Hormonal aspects might have a
function in PDAC as investigations on the expression of androgen
and oestrogen/progesterone receptors have demonstrated
(Andren-Sandberg et al, 1999; Konduri et al, 2007; Konduri
and Schwarz 2007; Lam et al, 2008). It would be interesting to
investigate the expression of the Hiwi gene – especially in tumours
of hormonally regulated or active organs – as it might give
additional clues to its function and regulative processes in humans.
As far as immunohistochemistry for Hiwi protein expression is
concerned, a strong positive staining in 26.9% of the carcinomas
(21 out of 78 patients) was observed, a rate substantially lower
than for mRNA transcript levels. These differences in the rates
of elevated Hiwi expression between mRNA and protein levels,
however, are very likely to be because of the much higher
sensitivity of the real-time PCR technique than that of IHC, thus
not allowing for detection of relevant Hiwi protein levels. Further-
more, a wide range of modified protein variants (e.g. post-
translational or other downstream modifications) might remain
undetected by IHC.
The detection rate of Hiwi mRNA transcripts and the association
with a gender-dependent risk pattern underscores the involvement
of stem cell-associated genes in carcinogenesis and cancer
development in PDAC. Given the tumour’s aggressive potential
and frequent changes in the Hiwi mRNA levels, Hiwi as a stem cell-
associated gene may have general and early impact on tumour-
igenesis in PDAC. A comparison of expression levels in PDAC and
in the normal pancreas could help to relate expression levels to
tumour biological behaviour. Altogether, the gene might be a
potential important target for further investigation in carcinogen-
esis and therapy of this dismal disease.
In summary, we demonstrate for the first time the expression of
the stem cell-associated Hiwi gene – a human homologue of the
Piwi family – in human PDAC and identify Hiwi as a potential
target for further investigation in carcinogenesis and therapy of
this dismal disease. The detection rate of Hiwi mRNA in clinically
apparent advanced PDAC and the lack of the gene’s significant
impact on tumour-related death, in general, might be indicative of
the tumour’s aggressive potential and hints at a broad and early
impact of the Hiwi gene in carcinogenesis of PDAC. Intriguingly,
alterations in mRNA expression levels of Hiwi can increase the risk
of tumour-related death in male patients, pointing at gender
differences in the prognostic impact of Hiwi mRNA expression in
PDAC.
ACKNOWLEDGEMENTS
We thank T Ko ¨hler, A Rost (AJ Roboscreen GmbH, Leipzig,
Germany) and T Hillebrand (AJ Innuscreen GmbH, Berlin,
Germany) for assistance with RNA analysis, S Sto ¨hr (Institute of
Medical Biometrics, University of Ulm, Ulm, Germany) for help
with statistical analysis, A Mayer for assistance with IHC-staining
and N Su ¨ssner for tissue preparation for microdissection and IHC.
HT’s study was supported by the Deutsche Krebshilfe Miltred
Scheel Stiftung (project: 107590 associated to KOSAR, Germany).
Supplementary Information accompanies the paper on British
Journal of Cancer website (http://www.nature.com/bjc)
REFERENCES
Andren-Sandberg A, Hoem D, Ba ¨ckman PL (1999) Other risk factors for
pancreatic cancer: hormonal aspects. Ann Oncol 10: 131–135
Aravin AA, Hannon GJ, Brennecke J (2007) The Piwi-piRNA pathway
provides an adaptive defense in the transposons arms race. Science 318:
761–764
Burgemeister R, Gangnus R, Haar B, Schu ¨tze K, Sauer U (2003) High quality
RNA retrieved from samples obtained by using LMPC (laser microdissec-
tion and pressure catapulting) technology. Pathol Res Pract 199: 431–436
Chen L, Shen R, Ye Y, Pu XA, Liu X, Duan W, Wen J, Zimmerer J, Wang Y,
Liu Y, Lasky LC, Heerema NA, Perrotti D, Ozato K, Kuramochi-
Miyagawa S, Nakano T, Yates AJ, Carson III WE, Lin H, Barsky SH, Gao
JX (2007) Precancerous stem cells have the potential for both benign and
malignant differentiation. PloS ONE 2: e293. doi:10.1371/journal.
pone.0000293
Cox DN, Chao A, Baker J, Chang L, Qiao D, Lin H (1998) A novel class of
evolutionary conserved genes defined by piwi are essential for stem cell
self-renewal. Genes Dev 12: 3715–3727
Deng W, Lin H (2002) Miwi, a murine homolog of piwi, encodes a
cytoplasmic protein essential for spermatogenesis. Dev Cell 2: 819–830
Farazi TA, Juranek SA, Tuschl T (2008) The growing catalogue of small
RNAs and their association with distinct Argonaute/Piwi family
members. Development 135(7): 1201–1214. February (e-pub ahead of
print)
Girard A, Sachidanandam R, Hannon GJ, Carmell MA (2006) A germline-
specific class of small RNAs binds mammalian Piwi proteins. Nature 442:
199–202, doi:10.1038/nature04917
Hutvagner G, Simard MJ (2008) Argonaute proteins: key players in RNA
silencing. Nat Rev Mol Cell Biol 9: 22–32
Konduri S, Schwarz MA, Cafasso D, Schwarz RE (2007) Androgen receptor
blockade in experimental combination therapy of pancreatic cancer.
J Surg Res 142: 378–386
Konduri S, Schwarz RE (2007) Estrogen receptor beta/alpha ratio predicts
response of pancreatic cancer cells to estrogens and phytoestrogens.
J Surg Res 140: 55–66
Kuramochi-Miyagawa S, Kimura T, Ijiri TW, Isobe T, Asada N, Fujita Y,
Ikawa M, Iwai N, Okabe M, Deng W, Lin H, Matsuda Y, Nakano T (2004)
Mili, a mammalian member of piwi family gene, is essential for
spermatogenesis. Development 131: 839–849
Hiwi: expression and prognosis in PDAC
LF Grochola et al
1087
British Journal of Cancer (2008) 99(7), 1083–1088 & 2008 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sLam MM, Swanson PE, Upton MP, Yeh MM (2008) Ovarian-type
stroma in hepatobiliary cystadenomas and pancreatic mucinous
cystic neoplasms: an immunohistochemical study. Am J Clin Pathol
129: 211–218
Liu X, Yu S, Guo J, Ma H, Li J, Dong B, Jiu G, Zhang J, Wu J, Meng L,
Shou C (2006) Expression of Hiwi gene in human gastric cancer
was associated with proliferation of cancer cells. Int J Cancer 118:
1922–1929
Qiao D, Zeeman AM, Deng W, Looijenga LHJ, Lin H (2002) Molecular
characterization of Hiwi, a human member of the piwi gene family whose
overexpression is correlated to seminomas. Oncogene 21: 3988–3999
Seto AG, Kingston RE, Lau NC (2007) The coming of age for Piwi proteins.
Mol Cell 26: 603–609
Sharma AK, Nelson MC, Brandt JE, Wessman M, Mahmud N, Weller KP,
Hoffman R (2001) Human CD34
+ stem cells express the Hiwi gene,
a human homologue of the Drosophila gene piwi. Blood 97: 426–434
Soltysova A, Alterenova V, Altaner C (2005) Cancer stem cells. Neoplasma
52: 435–440
Taubert H, Greither T, Kaushal D, Wu ¨rl P, Bache M, Bartel F, Kehlen A,
Lautenschla ¨ger C, Harris L, Kraemer K, Meye A, Kappler M, Schmid H,
Holzhausen HJ, Hauptmann S (2007a) Expression of the stem cell
self-renewal gene Hiwi and risk of tumour-related death in patients with
soft-tissue sarcoma. Oncogene 26: 1098–1100
Taubert H, Wu ¨rl P, Greither T, Kappler M, Bache M, Bartel F, Kehlen A,
Lautenschla ¨ger C, Harris LC, Kaushal D, Fu ¨ssel S, Meye A, Bo ¨hnke A,
Schmidt H, Holzhausen HJ, Hauptmann S (2007b) Stem cell-associated
genes are extremely poor prognostic factors for soft-tissue sarcoma
patients. Oncogene 26: 7170–7174
Yeo TP, Hruban RH, Leach SD, Wilentz RE, Sohn TA, Kern SE, Iacobuzio-
Donahue CA, Maitra A, Goggins M, Canto MI, Abrams RA, Laheru D,
Jaffee EM, Hidalgo M, Yeo CJ (2002) Pancreatic cancer. Curr Prob Cancer
26: 176–275
Hiwi: expression and prognosis in PDAC
LF Grochola et al
1088
British Journal of Cancer (2008) 99(7), 1083–1088 & 2008 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
s